Feedback / Questions
N, N-dimethyltryptamine (BMND01) - Biomind
https://www.businesswire.com/news/home/20220426005767/en/Biomind-Labs-Doses-First-Subject-in-Phase-IIIa-Clinical-Trial-of-Its-DMT-Based-Inhaled-Formulation-BMND01-for-Treatment-Resistant-Depression
Apr 26, 2022
SHARE THIS
Print
Email
More sharing
Reddit
StumbleUpon
Delicious
Prev
Next